Photodynamic activity of hypericin in human urinary bladder carcinoma cells

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2579-2584

  Kamuhabwa, Appolinary R ^a   Agostinis, Patrizia ^b   D'Hallewin, Marie Ange ^b   Kasran, Ahamad ^b   De Witte, Peter A ^a  

^a Faculteit Farmaceutische Wetenschappen   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bladder cancer; Hypericin; PDT; Photocytotoxicity

Indexed keywords

HYPERICIN; PHOTOSENSITIZING AGENT;

ARTICLE; BLADDER CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACCUMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, NEOPLASM; FLUORESCENCE; HUMANS; PERYLENE; PHOTOCHEMOTHERAPY; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033867005     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dougherty JT and Marcus SL: Photodynamic Therapy. Eur J Cancer 28A: 1734-1742, 1992.
2. Hahn SM and Glatstein HE: The emergency of photodynamic therapy as a major modality in cancer treatment. Rev Contemp Pharmacother 10: 69-79, 1999.
3. Dougherty JT, Corner JC, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic Therapy. J Natl Cancer 190: 889-905, 1998.
4. Nseyo U O, Shumaker B and Sutherland K : Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study group. J Urol 160: 39-44, 1998.
5. Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E and Kriegmair M: Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol 159: 401-404, 1998.
6. Kriegmair M, Baumgartner R, Lumper W, Waidelich A and Hofstetter A: Early clinical experience with 5 ammolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 77: 667-671, 1996.
7. D'Hallewin M A, Baert L, Marijnissen J P and Star W M: Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder. J Urol 148: 1152-1155, 1992.
8. Lavie G, Mazur Y, Lavie D and Meruelo D: The chemical and biological properties of hypericin -a compound with a broad spectrum of biological activities. Med Res Rev 15: 11-119, 1995.
9. Jardon P and Gautron R: Propriétés photophysiques de l'hypericine en solution et en dispersion micellaire. J Chim Phys 86: 2173-2190, 1989.
10. Diwu Z and Lown JW: Photosensitization with anticancer agents. 17. EPR studies of photodynamic action of hypericin: formation of semiquinone radical and activated oxygen species on illumination. Free Radic Biol Med 14: 209-215, 1993.
11. Vandenbogaerde AL, Geboes KR, Cuveele JF, Agostinis PM, Merlevede W and de Witte PA: Antitumor activity of photosensitized hypericin on A431 cell xenografts. Anticancer Res 16: 1611-1618, 1996.
12. Vandenbogaerde AL, Kamuhabwa A, Delaey E, Himpens BE, Merlevede WJ and de Witte PA: Photocytotoxicity effect of pseudohypericin versus hypericin. J Photochem Photobiol B 45: 87-79, 1998.
13. Assefa Z, Vantieghem A, Declercq W, Vandenabeele P, Vandenheede J, Merlevede W, de Witte P and Agostinis P: The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 274: 8788-8796, 1999.
14. Andreoni A, Colasanti A, Colasanti P, Mastrocinque M, Riccio P and Roberti G: Laser photosensitization of cells by hypericin. Photochem Photobiol 59: 529-533, 1994.
15. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss RE and Apuzzo ML: Hypericin: a potential antiglioma therapy. Neurosurgery 35: 705-709, 1994.
16. Okpanyi SN, Scholl BC and Miltenburger HG: Genotoxizität eines standardisierten Hypericum-Extraktes. Arzneim -Forsch 40: 851-866, 1990.
17. Falk H, Meyer J and Oberreiter M: A convenience semisynthetic route to hypericin. Monatsh Chem 124: 339-341, 1993.
18. Falk H and Schoppel G: On the synthesis of hypericin by oxidative trimethylemodin anthrone and emodin anthrone dimerization: isohypericin. Monatsh Chem 123: 931-938, 1992.
19. Pallombella VJ and Vicek J: Mitogenic and cytotoxic actions of tumor necrosis factor in BALB/c 3T3 cells. J Biol Chem 264: 18128-18136, 1989.
20. Yamazaki T, Ohta N, Yamazaki I and Song P-S: Excited state properties of hypericin: electron spectra and fluorescence decay kinetics. J Phys Chem 97: 7870-7875, 1993.